Diabetes cell therapies take evasive action
Elie Dolgin • February 25, 2022
Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.
Continue reading at Nature Biotechnology.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.
Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.